Switzerland: Expansion Strategy Lonza to Further Invest in Drug Product Manufacturing Services in Swiss

Editor: Ahlam Rais

Lonza has plans to expand its drug product development and manufacturing network in Switzerland. The company’s investment also includes the installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel (CH).

Related Company

To support Lonza's global drug product capacity increase, the investment will be accompanied by a footprint extension of its Drug Product Services (DPS) for parenteral dosage forms in Basel (CH).
To support Lonza's global drug product capacity increase, the investment will be accompanied by a footprint extension of its Drug Product Services (DPS) for parenteral dosage forms in Basel (CH).
(Source: Lonza)

Basel/Switzerland – Lonza has announced that it will invest in additional drug product manufacturing capabilities in Switzerland. This investment will fund an additional aseptic flexible filling line for clinical supply of drug product in Stein (CH).

The new line will support liquid and lyophilized vial filling and processing, cartridges and pre-filled syringes. The new filling line will allow Lonza to process various modalities, including monoclonal antibodies, bioconjugates, viral vectors, and other gene therapy products, for its customers. The filling line will utilize state-of-the-art robotic technology and implement innovative freeze-drying technology with a sustainable air-cooling system. The installation is expected to be completed in 2023 and will create more than 70 new positions at the Stein (CH) site.

The additional flexible filling line and footprint expansion of Lonza DPS will complement the drug product manufacturing capacity at the Visp (CH) site expected to come online in the first half of 2022.

To support Lonza's global drug product capacity increase, the investment will be accompanied by a footprint extension of its Drug Product Services (DPS) for parenteral dosage forms in Basel (CH). This expansion will further support the pharmaceutical development for early and late clinical stages and increase the process development and characterization capabilities offered from the Stücki Technologiepark in Basel. The expansion will strengthen the integrated drug substance and drug product offering across multiple modalities. The new DPS facilities in Basel (CH) are expected to be operational in 2024.

Jean-Christophe Hyvert, President, Biologics and Cell and Gene, Lonza, commented: "The drug product capability expansions in Switzerland provide our customers with access to a flexible, integrated offering comprising the development, testing and manufacturing services for mammalian, microbial, bioconjugate products, cell and gene therapies, and small molecules."

The additional flexible filling line and footprint expansion of Lonza DPS will complement the drug product manufacturing capacity at the Visp (CH) site expected to come online in the first half of 2022. As part of the Ibex Solutions biopark, the offering will support aseptic drug product manufacturing and filling of liquid and lyophilized vials.

(ID:47695506)